IP Library › Granted Patent US 12,435,046
Granted Patent B2
US 12,435,046 · App. 17/635,578 · Granted Oct 7, 2025

Alkynyl quinazoline compounds

Inventors: Matthew C. Lucas (Lexington, MA); Fernando Padilla (Arlington, MA); Alexander Flohr (Basel, CH); Luca Arista (Riehen, CH); Elizabeth Buck (Huntington, NY)
Assignee: Black Diamond Therapeutics, Inc.
C07D239/94A61P35/00C07D401/10C07D401/14C07D403/10C07D403/14C07D405/10C07D405/14C07D471/04C07D471/08C07D491/10C07D498/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,046
App. No.
17/635,578
Granted
Oct 7, 2025
Kind
B2
Abstract

The present disclosure relates to compounds of Formula (I′): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Claims (112)

1. A compound selected from:

Com-

pound

No.

Structure

 1

 2

 3

 4

 5

 6

 7

 8

10

11

12

13

14

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

37A

37B

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

and pharmaceutically acceptable salts thereof.

2. A composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.

3. A compound of which is

or a pharmaceutically acceptable salt thereof.

4. A composition comprising the compound of claim 3 , and a pharmaceutically acceptable carrier.

5. A compound of which is

or a pharmaceutically acceptable salt thereof.

6. A composition comprising the compound of claim 5 , and a pharmaceutically acceptable carrier.

7. The compound of claim 1 , being which is

or a pharmaceutically acceptable salt thereof.

8. A composition comprising the compound of claim 7 , and a pharmaceutically acceptable carrier.

9. A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering to a subject in need thereof a compound of claim 1 .

10. A method of treating cancer, comprising administering to the subject a compound of claim 1 .

11. The method of claim 10 , wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

12. A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering to the subject in need thereof the compound of claim 3 .

13. A method of treating cancer, comprising administering to the subject in need thereof the compound of claim 3 .

14. The method of claim 13 , wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

15. A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering to the subject in need thereof the compound of claim 5 .

16. A method of treating cancer, comprising administering to the subject in need thereof the compound of claim 5 .

17. The method of claim 16 , wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

18. A method of inhibiting an oncogenic variant of an ErbB receptor, comprising administering to the subject in need thereof the compound of claim 7 .

19. A method of treating cancer, comprising administering to the subject in need thereof the compound of claim 7 .

20. The method of claim 19 , wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2025
From: ARISTA, LUCA; FLOHR, ALEXANDER
To: RIDGELINE THERAPEUTICS GMBH
Reel/Frame 071808/0871 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2025
From: RIDGELINE THERAPEUTICS GMBH
To: BLACK DIAMOND THERAPEUTICS, INC.
Reel/Frame 071808/0980 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 061350 FRAME: 0247. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 12, 2023
From: LUCAS, MATTHEW C.; PADILLA, FERNANDO; FLOHR, ALEXANDER; ARISTA, LUCA; BUCK, ELIZABETH
To: BLACK DIAMOND THERAPEUTICS, INC.
Reel/Frame 062387/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2022
From: LUCAS, MATTHEW C.; PADILLA, FERNANDO; FLOHR, ALEXANDER; ARISTA, LUCA; BUCK, ELIZABETH
To: BLACK DIAMOND THERAPEUTICS
Reel/Frame 061350/0247 →
Continuity (3)
Provisional Application 63065028 · Aug 13, 2020
Provisional Application 62887392 · Aug 15, 2019
Related Publication 20220298120A1 · Sep 22, 2022
References Cited (156)
US 6127374A · Bridges · 2000 [cited by applicant]
US 6867201B2 · Kath et al. · 2005 [cited by applicant]
US 7294629B2 · Kitano · 2007 [cited by examiner]
US 8735409B2 · Zhang et al. · 2014 [cited by applicant]
US 8987284B2 · Shen et al. · 2015 [cited by applicant]
US 9090588B2 · Shen et al. · 2015 [cited by applicant]
US 9187459B2 · Shen et al. · 2015 [cited by applicant]
US 9890187B2 · Odysseos et al. · 2018 [cited by applicant]
US 10221191B2 · Hadari et al. · 2019 [cited by applicant]
US 10309966B2 · Sibilia · 2019 [cited by applicant]
US 10640524B2 · Odysseos et al. · 2020 [cited by applicant]
US 10870657B2 · Hadari et al. · 2020 [cited by applicant]
US 11034672B1 · Flohr et al. · 2021 [cited by applicant]
US 20080200433A1 · Suzuki et al. · 2008 [cited by applicant]
US 20100087482A1 · Haber et al. · 2010 [cited by applicant]
US 20130035350A1 · Zhang et al. · 2013 [cited by applicant]
US 20150126537A1 · Zhang · 2015 [cited by applicant]
US 20160039838A1 · Zhang et al. · 2016 [cited by applicant]
US 20190382382A1 · Shen et al. · 2019 [cited by applicant]
US 20200299315A1 · Shen et al. · 2020 [cited by applicant]
US 20220041613A1 · Flohr et al. · 2022 [cited by applicant]
US 20220273665A1 · McGovern et al. · 2022 [cited by applicant]
US 20220340523A1 · Dakin et al. · 2022 [cited by applicant]
US 20220363666A1 · Flohr et al. · 2022 [cited by applicant]
US 20240075042A1 · Buck et al. · 2024 [cited by applicant]
US 20240425492A1 · Zhang · 2024 [cited by applicant]
CN 1492860A · 2004 [cited by applicant]
CN 101010304A · 2007 [cited by applicant]
CN 101679384A · 2010 [cited by applicant]
CN 102382065A · 2012 [cited by applicant]
CN 102452989A · 2012 [cited by applicant]
CN 102516232A · 2012 [cited by applicant]
CN 102731485A · 2012 [cited by applicant]
CN 103797006A · 2014 [cited by applicant]
CN 103965120A · 2014 [cited by applicant]
CN 103998040A · 2014 [cited by applicant]
CN 104119350A · 2014 [cited by applicant]
CN 105348271A · 2016 [cited by applicant]
CN 108473464A · 2018 [cited by applicant]
CN 109265449A · 2019 [cited by applicant]
CN 113382986A · 2021 [cited by applicant]
EP 1249451A2 · 2002 [cited by applicant]
EP 1369418A1 · 2003 [cited by applicant]
EP 1000039B1 · 2004 [cited by applicant]
EP 1506962A2 · 2005 [cited by applicant]
EP 1792898A1 · 2007 [cited by applicant]
EP 2612860A1 · 2013 [cited by applicant]
JP 5155391B2 · 2013 [cited by applicant]
JP 2014518544A · 2014 [cited by applicant]
WO WO9630347A1 · 1996 [cited by applicant]
WO WO9738983A1 · 1997 [cited by applicant]
WO WO9906378A1 · 1999 [cited by applicant]
WO WO9909016A1 · 1999 [cited by applicant]
WO WO0044728A1 · 2000 [cited by applicant]
WO WO0047212A1 · 2000 [cited by applicant]
WO WO0078735A1 · 2000 [cited by applicant]
WO WO0177104A1 · 2001 [cited by applicant]
WO WO0218370A1 · 2002 [cited by applicant]
WO WO0250043A1 · 2002 [cited by applicant]
WO WO02066445A1 · 2002 [cited by applicant]
WO WO03045939A1 · 2003 [cited by applicant]
WO WO03089439A1 · 2003 [cited by applicant]
WO WO2004069791A2 · 2004 [cited by applicant]
WO WO2005026157A1 · 2005 [cited by applicant]
WO WO2005107758A1 · 2005 [cited by applicant]
WO WO2006025490A1 · 2006 [cited by applicant]
WO WO2007013950A2 · 2007 [cited by applicant]
WO WO2007055513A1 · 2007 [cited by applicant]
WO WO2007055514A1 · 2007 [cited by applicant]
WO WO2008020711A1 · 2008 [cited by applicant]
WO WO2008033749A2 · 2008 [cited by applicant]
WO WO2008150118A2 · 2008 [cited by applicant]
WO WO2008157500A1 · 2008 [cited by applicant]
WO WO2010036629A2 · 2010 [cited by applicant]
WO WO2012122058A2 · 2012 [cited by applicant]
WO WO2012136099A1 · 2012 [cited by applicant]
WO WO2013008217A1 · 2013 [cited by applicant]
WO WO2013013640A1 · 2013 [cited by applicant]
WO WO2013131424A1 · 2013 [cited by applicant]
WO WO2013173254A1 · 2013 [cited by applicant]
WO WO2014007951A2 · 2014 [cited by applicant]
WO WO2014071824A1 · 2014 [cited by applicant]
WO WO2014177038A1 · 2014 [cited by applicant]
WO WO2015043515A1 · 2015 [cited by applicant]
WO WO2015054572A1 · 2015 [cited by applicant]
WO WO2016023217A1 · 2016 [cited by applicant]
WO WO2016055982A1 · 2016 [cited by applicant]
WO WO2016105582A1 · 2016 [cited by applicant]
WO WO2016203406A1 · 2016 [cited by applicant]
WO WO2017055859A1 · 2017 [cited by applicant]
WO WO2020068867A1 · 2020 [cited by applicant]
WO WO2020068873A1 · 2020 [cited by applicant]
WO WO2021030711A1 · 2021 [cited by applicant]
WO WO2021154997A1 · 2021 [cited by applicant]
WO WO2021195206A1 · 2021 [cited by applicant]
WO WO2021213800A1 · 2021 [cited by applicant]
WO WO2022040377A1 · 2022 [cited by applicant]
WO WO2022076671A1 · 2022 [cited by applicant]
WO WO2022094464A1 · 2022 [cited by applicant]
WO WO2023049168A1 · 2023 [cited by applicant]
WO WO2025038731A1 · 2025 [cited by applicant]
Sattler, M. et al., “A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine,” J Clin Med. Mar. 1, 2023;12(5):1936, 13 pages, doi: 10.3390/jcm12051936. [cited by applicant]
Wang, D.D. et al., “Personalized prediction of EGFR mutation-induced drug resistance in lung cancer,” Scientific Reports, 2013;3:2855, DOI: 10.1038/srep02855, 8 pages. [cited by applicant]
Argiris, A et al., “Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial,” Journal of Clinica… [cited by applicant]
Asadollahi-Baboli, M., “In silica evaluation, molecular docking and QSAR analysis of quinazoline—based EGFR-T790M inhibitors,” Mol Divers, 20:729-739 (2016). [cited by applicant]
Blair et al., “Structure-guided development of affinity probes for tyrosine kinases using chemical genetics,” Nature Chemical Biology, Apr. 2007, 3:229-238. [cited by applicant]
Caira, M. R., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry (Jan. 1, 1998); 198:163-208. [cited by applicant]
Carmi, C. et al. “Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides,” J. Med. Chem., Jan. 26, 2012, 55:2251-2264 (including Supporting Information, 25 pages total). [cited by applicant]
CAS Registry No. 1012054-59-9, dated Apr. 4, 2008, 1 page. [cited by applicant]
CAS Registry No. 1092364-38-9, dated Dec. 31, 2008, 1 page. [cited by applicant]
CAS Registry No. 1110813-31-4, dated Feb. 23, 2009, 1 page. [cited by applicant]
CAS Registry No. 1131863-89-2, dated Apr. 3, 2009, 1 page. [cited by applicant]
CAS Registry No. 1197953-54-0, dated Dec. 17, 2009, 1 page. [cited by applicant]
CAS Registry No. 1213269-23-8, dated Mar. 23, 2010, 1 page. [cited by applicant]
CAS Registry No. 1214265-56-1, dated Mar. 24, 2010, 1 page. [cited by applicant]
CAS Registry No. 1214265-57-2, dated Mar. 24, 2010, 1 page. [cited by applicant]
CAS Registry No. 1374640-70-6, dated May 29, 2012, 1 page. [cited by applicant]
CAS Registry No. 1398833-56-1, dated Oct. 3, 2012, 1 page. [cited by applicant]
CAS Registry No. 1421373-65-0, dated Feb. 19, 2013, 1 page. [cited by applicant]
CAS Registry No. 183319-69-9, dated Nov. 22, 1996, 1 page. [cited by applicant]
CAS Registry No. 184475-35-2, dated Dec. 26, 1996, 1 page. [cited by applicant]
CAS Registry No. 187724-61-4, dated Mar. 28, 1997, 1 page. [cited by applicant]
CAS Registry No. 194423-15-9, dated Sep. 24, 1997, 1 page. [cited by applicant]
CAS Registry No. 196612-93-8, dated Oct. 31, 1997, 1 page. [cited by applicant]
CAS Registry No. 212141-54-3, dated Oct. 4, 1998, 1 page. [cited by applicant]
CAS Registry No. 231277-92-2, dated Aug. 7, 1999, 1 page. [cited by applicant]
CAS Registry No. 257933-82-7, dated Mar. 3, 2000, 1 page. [cited by applicant]
CAS Registry No. 267243-28-7, dated May 30, 2000, 1 page. [cited by applicant]
CAS Registry No. 439081-18-2, dated Jul. 17, 2002, 1 page. [cited by applicant]
CAS Registry No. 443913-73-3, dated Aug. 14, 2002, 1 page. [cited by applicant]
CAS Registry No. 451493-31-5, dated Sep. 16, 2002, 1 page. [cited by applicant]
CAS Registry No. 497839-62-0, dated Mar. 11, 2003, 1 page. [cited by applicant]
CAS Registry No. 610798-31-7, dated Oct. 30, 2003, 1 page. [cited by applicant]
CAS Registry No. 692737-80-7, dated Jun. 14, 2004, 1 page. [cited by applicant]
CAS Registry No. 698387-09-6, dated Jun. 24, 2004, 1 page. [cited by applicant]
CAS Registry No. 714971-09-2, dated Jul. 23, 2004, 1 page. [cited by applicant]
CAS Registry No. 781613-23-8, dated Nov. 16, 2004, 1 page. [cited by applicant]
CAS Registry No. 848133-17-5, dated Apr. 8, 2005, 1 page. [cited by applicant]
CAS Registry No. 848942-61-0, dated Apr. 21, 2005, 1 page. [cited by applicant]
CAS Registry No. 871026-44-7, dated Jan. 3, 2006, 1 page. [cited by applicant]
CAS Registry No. 897383-62-9, dated Jul. 28, 2006, 1 page. [cited by applicant]
CAS Registry No. 934660-93-2, dated May 13, 2007, 1 page. [cited by applicant]
Dermer, G.B., “Another Anniversary for the War on Cancer,” Bio/Technology, 12:320, 1 page (Mar. 1994). [cited by applicant]
Freshney R.I., et al., “Culture of Animal Cells,” A Manual of Basic Technique, 1983, Alan R. Liss, Inc., New York, p. 4. [cited by applicant]
Golub, T. R., et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring”, Science (1999); 286: 531-537. [cited by applicant]
Martins, R. G. et al., “Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial,” Journal of Clinical Oncology, 31(11):1415-1421… [cited by applicant]
Peereboom, D. M. et al., “Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme,” J Neurooncol, 98:93-99 (2010). [cited by applicant]
Petrylak, D. P. et al., “Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium,” Southwest Oncology Group, 105:317-321 (2009); doi… [cited by applicant]
Philips, G. K. et al., “A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102,” Annals of Oncology, 20:1074-1079 (… [cited by applicant]
Reardon, D.A. et al., “Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma,” Neuro-Oncology, Advance Access p… [cited by applicant]
Shen, W. et al. “A41 EO1001: A First-in-Class Irreversible Pan-ErbB Inhibitor with Excellent Brain Penetration,” Journal of Thoracic Oncology, 15(2 Suppl):S26, Abstract A41 (Feb. 2020). [cited by applicant]
Shen, W. et al. “NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance,” [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Re… [cited by applicant]
Simone, J. V. (1996) “Introduction” in Cecil Textbook of Medicine. 20th Ed., vol. I . J. Claude Bennet and F. Plum (Eds.) W.B. Sauders Co.; pp. 1004-1010. [cited by applicant]
Van Den Bent, M. J. et al., “Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034,” J Clin Oncol, 27:1268-1274 (2009). [cited by applicant]
Yin, D. et al. “Studying the Conformation of a Receptor Tyrosine Kinase in Solution by Inhibitor-Based Spin Labeling,” Angew Chem Int Ed Engl., 56(29):8417-8421, with Supporting Information, 24 pages (Jul. 10, 2017). do… [cited by applicant]
Yoshida, Y. et al. “NT113, a pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification,” Mol. Cancer Ther., Dec. 2014, 13(12):2919-29. [cited by applicant]
Cited By (1)
US 12,714,713